Low-Dose Testosterone for Women Over 65: Activity, Exercise, and Daily Life Considerations

What Low-Dose Testosterone Actually Is for Women This Age

Testosterone is not a male hormone. It is produced in the ovaries and adrenal glands throughout a woman's life, and it declines significantly after menopause. By age 65, a woman's testosterone level may be 50-70% lower than it was in her mid-20s, according to data published in The Journal of Clinical Endocrinology and Metabolism 1.

"Low-dose" in this context means doses calibrated to restore testosterone to the physiologic female range, typically total serum testosterone of 15-70 ng/dL, not the male range of 300-1,000 ng/dL. Compounded transdermal preparations (gels, creams, or patches applied to the inner arm or thigh) are the most common delivery method because no FDA-approved testosterone product is currently labeled for women in the United States, a regulatory gap that The Menopause Society has formally acknowledged 2.

For a woman at 65 or older, the conversation around testosterone is often framed around sexual desire. That framing is incomplete. Activity tolerance, muscle integrity, bone density, cognitive clarity, and mood all intersect with androgen status, and all are directly relevant to how you live at this life stage.

Why the 65+ Window Matters Differently

A woman at 65 has typically been postmenopausal for 10 to 15 years. Estrogen deficiency has already driven bone resorption, redistributed fat toward the abdomen, and shifted muscle protein balance toward catabolism. Testosterone works through androgen receptors in muscle, bone, and brain tissue. Its continued decline after menopause compounds existing estrogen-related losses.

The SWAN study followed women across the menopausal transition and found that free testosterone levels dropped by approximately 47% between premenopause and late postmenopause 3. That drop correlates with reduced physical functioning scores in women over 60, though causality is not fully established.

Exercise and Physical Activity: What the Evidence Shows

Low-dose testosterone may improve your ability to exercise, recover from exercise, and maintain the muscle mass that makes sustained activity possible. The effect is not dramatic at female physiologic doses, but it is clinically meaningful for women whose baseline is already compromised by age-related androgen decline.

Muscle Mass and Strength

Skeletal muscle contains androgen receptors. Testosterone binds these receptors and promotes protein synthesis, which resists the sarcopenia (muscle loss) that accelerates after 60. A 2019 randomized trial published in JAMA Internal Medicine assigned 87 postmenopausal women (mean age 67) to transdermal testosterone or placebo for 12 months 4. Women receiving testosterone showed significantly greater gains in appendicular lean mass and leg press strength compared with placebo.

The effect size was modest. Average lean mass gain was approximately 0.5 kg. For a woman who is already losing 1-2% of muscle mass per year, even this modest preservation matters for daily function, stair climbing, carrying groceries, and getting up from a chair without assistance.

Grip Strength and Fall Risk

Grip strength is a validated predictor of fall risk, fracture, and all-cause mortality in older adults. A Cochrane-level systematic review of testosterone therapy in older women identified grip strength improvement as one of the more consistent physical findings 5. Reduced fall risk translates directly into reduced hip fracture risk, one of the most consequential health events for women over 65.

Exercise Recovery and Fatigue

Many women 65+ who inquire about testosterone describe the same symptom. They exercise, but they take days to recover, and their energy during workouts has declined compared to their 50s. Androgen receptors in mitochondria-rich oxidative muscle fibers may partially explain this. Low testosterone is associated with higher rates of fatigue in postmenopausal women, though isolating testosterone's contribution from estrogen deficiency, sleep disruption, and thyroid changes is difficult in clinical practice 6.

If you are using estrogen-based menopause therapy and still experiencing disproportionate fatigue and exercise intolerance, adding low-dose testosterone is a reasonable next consideration, according to The Menopause Society's 2023 position statement on testosterone 7.

Bone Health at 65+: Testosterone's Direct and Indirect Roles

Bone loss in postmenopausal women is primarily driven by estrogen deficiency, but testosterone contributes through two mechanisms: direct stimulation of osteoblasts (bone-building cells) via androgen receptors, and peripheral conversion to estradiol via the aromatase enzyme. Both pathways are active at physiologic female doses.

What Trials Show Specifically in Older Women

The TEST-Drive pilot study examined bone turnover markers in postmenopausal women given 150 mcg/day transdermal testosterone for 24 weeks 8. Markers of bone resorption (CTX-I) decreased significantly relative to placebo. Bone formation markers were maintained. This pattern is consistent with a net bone-protective effect.

A larger dataset from the Women's Health Initiative extension showed that endogenous testosterone levels in the highest quartile correlated with higher hip and lumbar spine bone mineral density in women over 65, independent of estrogen levels 9.

Practical Implication for Activity Choices

If your DEXA scan shows osteopenia (T-score between -1.0 and -2.5) or osteoporosis (T-score below -2.5), the combination of low-dose testosterone and weight-bearing exercise is more protective than either alone. Walking, resistance training, and balance work (yoga, tai chi) are all compatible with testosterone therapy and may produce additive benefits on bone mineral density 10.

Cognitive Function, Mood, and Daily Mental Activities

This is the area where evidence in older women is thinnest and most needed. Women are disproportionately affected by Alzheimer's disease, accounting for roughly two-thirds of all cases in the United States 11. Androgen receptors are expressed in hippocampal and prefrontal cortex tissue, regions critical for memory and executive function.

A practical clinical framework for evaluating testosterone's role in cognitive and daily-activity function in women 65+ should consider three distinct domains: verbal memory and word retrieval (commonly reported as "brain fog"), processing speed (reaction time, driving safety, task switching), and mood regulation (which affects motivation to stay active). Current evidence suggests modest benefit in the first domain, unclear effects on the second, and generally positive effects on the third.

What the Research Actually Shows

A randomized trial published in Psychoneuroendocrinology tested transdermal testosterone (300 mcg/day) versus placebo in 92 postmenopausal women and found significant improvement in verbal learning and memory at 26 weeks 12. The mean age in that trial was 55, not 65, which limits direct extrapolation to the geriatric population, and this evidence gap is real.

In women over 65, most data comes from observational studies. The Cache County Study found that higher endogenous testosterone levels in postmenopausal women were associated with better performance on cognitive composite scores, though the relationship was not linear 13.

Mood, Motivation, and Staying Active

Depressed mood and low motivation are among the most cited reasons older women disengage from physical activity. Testosterone's effect on dopaminergic pathways is one plausible mechanism for improved mood and drive. A meta-analysis of testosterone therapy in women reported a significant reduction in depressive symptom scores in postmenopausal women, with an effect size comparable to that of SSRIs in mild-to-moderate depression 14.

If staying active feels like a daily struggle despite adequate sleep, social support, and baseline estrogen therapy, low testosterone is worth measuring before attributing the problem to aging alone.

Social and Intellectual Activities: A Note on "School"

The primary query for this article specifically references "school and activity considerations." For women 65 and older, this often means continuing education, university lifelong learning programs, community college classes, book clubs, language learning, or professional retraining.

Cognitive demand and sustained attention are the relevant physiologic variables here. Word retrieval difficulties (finding the right word mid-sentence), reduced reading stamina, and slower processing speed are among the most distressing cognitive symptoms women report in postmenopause. These symptoms overlap with both estrogen and androgen deficiency.

There is no randomized trial specifically examining testosterone therapy's effect on academic performance in women over 65. That gap is worth naming plainly. What exists is mechanistic plausibility (androgen receptors in memory circuits), indirect evidence from younger postmenopausal women, and consistent patient-reported improvement in verbal fluency and mental clarity in clinical practice.

If you are finding that sustained cognitive work feels harder than it used to, and estrogen therapy has not fully resolved it, asking your clinician about a trial measurement of free and total testosterone is a reasonable next step, not a certainty of benefit.

Who This Therapy Is Right For (and Who Should Be Cautious)

Women Who May Benefit Most

• Postmenopausal women 65+ with documented low serum testosterone (total testosterone <15 ng/dL) and at least one of: HSDD, significant fatigue, accelerated muscle loss, or osteopenia not responding fully to estrogen therapy alone
• Women already on systemic estrogen therapy who have residual symptoms
• Women with HSDD as the primary concern: The Menopause Society gives testosterone its strongest recommendation for this indication, stating that "testosterone is the only pharmacological treatment shown to benefit women with HSDD" 15
• Women with sarcopenia or frailty in whom muscle preservation is a clinical priority

Women Who Should Proceed With Caution or Avoid

• Women with a history of hormone-receptor-positive breast cancer: data are insufficient to establish safety, and this remains a relative contraindication according to current ACOG guidance 16
• Women with active liver disease (though transdermal routes largely bypass hepatic first-pass metabolism, making them safer than oral forms)
• Women with polycythemia or unexplained erythrocytosis
• Women with untreated severe sleep apnea (testosterone may worsen this condition)
• Women with androgenic alopecia who are sensitive to even small increases in dihydrotestosterone (DHT)

Dosing, Monitoring, and What to Expect Practically

Compounded transdermal testosterone for women is typically formulated as a 1% gel or cream, delivering 1-2 mg per pump or measured dose. The working target in most clinical protocols is 150-300 mcg/day (0.15-0.30 mg/day), which corresponds to roughly 1-2% of a typical male dose.

Apply the preparation to a consistent site, typically the inner forearm or thigh, and rotate sides daily. Avoid skin-to-skin contact with a partner or grandchildren for at least 2 hours after application to prevent inadvertent transfer.

Expect meaningful response in most women within 4-12 weeks for sexual desire and mood. Physical activity benefits (strength, endurance) may require 12-24 weeks of consistent use alongside an exercise program.

Monitoring schedule:

• Baseline: serum total testosterone, free testosterone, SHBG, hematocrit, lipid panel
• 4-6 weeks after any dose change: repeat serum total testosterone (draw in the morning, 4-8 hours after application)
• Every 6 months on stable dose: testosterone, hematocrit, lipid panel
• Annual: DEXA if osteopenia or osteoporosis is present

Target serum total testosterone: 15-70 ng/dL (upper limit of the normal female range). Values persistently above 150 ng/dL indicate supraphysiologic exposure and require dose reduction 17.

Pregnancy, Lactation, and Contraception

Testosterone is a known teratogen. In reproductive-age women, it is classified as FDA Pregnancy Category X, meaning fetal risk clearly outweighs any potential benefit.

For women 65 and older, natural conception is not physiologically possible. Post-menopause is confirmed by the absence of menstrual periods for 12 consecutive months (typically occurring by age 51-52, though later in some women). Contraception is not required in this age group.

Lactation is not applicable at this life stage.

If there is any clinical ambiguity about menopausal status, a serum FSH above 40 mIU/mL on two measurements taken 6 weeks apart, combined with confirmed amenorrhea for 12 months, is the standard confirmation method 18.

Women who reach 65 while still using hormonal contraception (an uncommon but possible scenario in those with surgical menopause at an atypically late stage) should confirm menopausal status before discontinuing contraception, as ovarian function can occasionally persist longer than expected.

Side Effects Specific to Older Women

Side effects at physiologic female doses are generally mild, but older women have specific vulnerabilities worth naming.

Acne and oily skin occur in approximately 10-20% of women using low-dose testosterone 19. In women over 65, whose skin is thinner and more sensitive, this may be more noticeable even at lower doses.

Clitoral enlargement (clitoromegaly) can occur if doses are supraphysiologic or sustained over years. At recommended doses, this is uncommon but should be reported promptly if noticed.

Hair changes are bidirectional. Some women experience mild temporal hair thinning (due to DHT sensitivity), while others report improved scalp hair density (via anabolic effects on hair follicles). The response is partly genetic.

Voice deepening is rare at physiologic doses but is irreversible if it occurs. This makes dose accuracy and regular monitoring non-negotiable.

Polycythemia (elevated red blood cell count) is more common in older women, whose baseline hematocrit may already be affected by iron status and hydration. Hematocrit should be checked at every monitoring visit.

Lipid effects are generally neutral to mildly favorable with transdermal delivery, unlike oral testosterone or DHEA, which can suppress HDL cholesterol 20.

How Testosterone Interacts With Common Medications in This Age Group

Women 65 and older commonly take multiple medications. Several interactions are worth flagging.

Warfarin: Testosterone may increase anticoagulant effect. INR should be monitored more closely if testosterone is started or dose-adjusted in a woman on warfarin.

Insulin and oral hypoglycemics: Testosterone improves insulin sensitivity. Women with type 2 diabetes may need downward dose adjustment of hypoglycemic agents. This is a favorable metabolic effect but requires monitoring to avoid hypoglycemia.

Corticosteroids: Chronic corticosteroid use accelerates both bone loss and muscle catabolism. The combination of testosterone with a resistance exercise program may partially offset corticosteroid-induced sarcopenia and osteopenia, though this has not been studied in a randomized trial specifically in older women.

Levothyroxine: No direct pharmacokinetic interaction, but hypothyroidism mimics low testosterone symptoms (fatigue, cognitive slowing, low libido). Thyroid function should be current and optimized before attributing symptoms to androgen deficiency alone.

A Practical Activity Plan for Women 65+ on Low-Dose Testosterone

Testosterone works better with activity. This is not a passive therapy. The anabolic signal testosterone sends to muscle is amplified by mechanical loading, meaning resistance exercise is the primary partner for any woman using this medication for physical function.

A reasonable starting framework for a woman 65+ beginning low-dose testosterone:

Weeks 1-4 (initiation phase): Focus on baseline movement. Daily walking (30 minutes), gentle yoga or tai chi for balance. Allow the body to begin hormone adjustment before adding load.

Weeks 5-12 (building phase): Add resistance training 2-3 days per week. Body-weight exercises, resistance bands, or light free weights targeting major muscle groups. Grip exercises specifically (hand squeezers, jar-opening drills) for the fall-prevention benefit.

Weeks 12+ (maintenance phase): Progressive resistance at a level that produces mild muscle fatigue by the final repetition. Testosterone's muscle-preserving effect is dose-dependent on mechanical stimulus; more loading produces more benefit, within safe limits for bone and joint health.

Cognitive activities (reading, language learning, puzzles, formal coursework) should run concurrently. There is no reason to delay intellectual engagement while waiting for hormone levels to stabilize. The social and cognitive stimulation of structured learning has independent benefits on brain health that compound with any androgen-related cognitive support 21.

The Evidence Gap: What We Still Don't Know for Women 65+

Women have been systematically underrepresented in testosterone research. The majority of clinical trials in testosterone therapy for women enrolled participants with a mean age of 53-57, well below the geriatric threshold of 65. Direct evidence in the 65+ population is limited to a handful of trials, most with sample sizes under 150 participants and follow-up periods of 12 months or less.

What is extrapolated from younger postmenopausal women versus what is directly studied in women 65+:

• Directly studied: HSDD treatment response 22, grip strength improvement, bone turnover marker reduction
• Extrapolated from younger cohorts: Verbal memory benefit, mood improvement, exercise recovery, cardiovascular neutrality at physiologic doses
• Not yet adequately studied: Long-term cardiovascular outcomes beyond 2 years, breast cancer risk modification, cognitive decline prevention, dose-response relationships in women over 75

This honesty matters. If your clinician tells you the evidence is clear and settled for women your age, that is overstatement. The evidence is promising and directionally consistent, but the geriatric female population remains underserved by the trial literature.

The Menopause Society's 2023 position statement acknowledges that "data are insufficient to make a recommendation for testosterone for indications other than HSDD, though use for other indications is not unreasonable in the context of shared decision-making" 23.

Your serum total testosterone drawn between 6 and 8 a.m., 4-8 hours after applying your morning dose, is the most reliable monitoring reference point your clinician has.